Synthetic lethal hubs associated with vincristine resistant neuroblastoma.
Fechete
Raul
R
Emergentec Biodevelopment GmbH, Gersthofer Strasse 29-31, 1180 Vienna, Austria.
Barth
Susanne
S
Olender
Tsviya
T
Munteanu
Andreea
A
Bernthaler
Andreas
A
Inger
Aron
A
Perco
Paul
P
Lukas
Arno
A
Lancet
Doron
D
Cinatl
Jindrich
J
Michaelis
Martin
M
Mayer
Bernd
B
D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000235:genetics / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D009363:Neoplasm Proteins / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009447:Neuroblastoma / Q000378:metabolism*; D038941:Polypyrimidine Tract-Binding Protein / Q000378:metabolism; D014750:Vincristine / Q000494:pharmacology*
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; C504334:PTBP2 protein, human; D038941:Polypyrimidine Tract-Binding Protein; D014750:Vincristine